Clinical Trials on Micro RNA

Total 23251 results

Bukwang Pharmaceutical

Terminated

Safety and Antiviral Activity of Clevudine in Patients Infected With Hepatitis B Virus

Hepatitis B

Korea, Republic of
Triangle Pharmaceuticals

Unknown

A Safety Study to Evaluate 12 Weeks of Treatment with Clevudine in Patients Infected with Hepatitis B Virus.

Hepatitis B

United States, Canada, China, France, Singapore
Sohag University

Recruiting

Prevalence of HBV in Pregnancy

Hepatitis B

Egypt
Merck Sharp & Dohme LLC

Completed

A Hepatitis B Vaccine Challenge Study After Previous Vaxelis® Vaccination (V419-013)

Hepatitis B

Finland
Hasselt University

Completed

Hepatitis B Virus Prevalence and Risk Factors in Belgium (HBVBE)

Hepatitis B

Belgium
Dynavax Technologies Corporation

Completed

Open-Label Study of the Safety and Immunogenicity of HEPLISAV™ Hepatitis B Virus Vaccine

Hepatitis B

United States
Gilead Sciences

Completed

Registry Study for Patients With Chronic HBV Receiving Nucleotide Therapy

Hepatitis B

United States, Canada
Bristol-Myers Squibb

Completed

Comparison of Entecavir to Adefovir in Chronic Hepatitis B Virus (HBV) Patients With Hepatic Decompensation

Hepatitis B

United States, France, India, Taiwan, Thailand, Turkey, United Kingdom, Brazil, Canada, Poland, Russian Federation, Singapore, Greece, South Africa, Hong Kong, Philippines, Indonesia
Sun Yat-sen University

Unknown

Efficacy of Peg-interferon α-2a in Hepatitis B Patients Treated by Entecavir Without HBeAg Loss

Hepatitis B

China
Laval University

Recruiting

Immunogenicity of 2 Versus 3 Doses of Combined Hepatitis B Vaccines in 2-18 Months Old Children

Hepatitis B

Canada
Hospices Civils de Lyon

Recruiting

Creation of a Cohort for the Quantitation and Characterization of Circulating Viral RNAs as a New Biomarker of Hepatitis B Functional Cure. (CirB-RNA)

Hepatitis B

France, Italy
PT Bio Farma

Completed

Safety and Immunogenicity Following Recombinant Hepatitis B (Bio Farma) Vaccine in Adults & Children

Hepatitis B

Indonesia
VBI Vaccines Inc.

Completed

Safety and Immunogenicity of Recombinant Hepatitis B Vaccine Sci-B-Vac® Compared to Engerix-B®

Hepatitis B

Russian Federation
Institut Pasteur

Withdrawn

Neonatal Vaccination Against Hepatitis B in Africa - Sero-survey in Senegal (NeoVac2S)

Hepatitis B
Baylor Research Institute

Completed

Safety and Efficacy of a Hepatitis B Vaccine in Immunosuppressed Patients

Hepatitis B

United States
Mount Sinai Hospital, Canada
University of Toronto

Withdrawn

Combination Hepatitis A and B Vaccine to Induce Immunity in Non-responders

Hepatitis B

Canada
Hasselt University

Unknown

Hepatitis B Prevalence in the Turkish Population Living in Middle Limburg (HBVTR)

Hepatitis B

Belgium
GlaxoSmithKline

Completed

Immuno & Safety Study of GSK Biologicals' Thio or Preservative Free Hepatitis B Vaccine in Subjects Aged 11-15 Yrs

Hepatitis B

Belgium, Ukraine, Australia
Maastricht University Medical Center
CyTuVax

Completed

Safety and Immunogenicity of HBAI20 Hepatitis B Vaccine in Naive Adults and Non-responders

Hepatitis B

Netherlands
GlaxoSmithKline

Completed

Antibody Persistence & Immune Memory in Healthy Adults Previously Vaccinated With Twinrix Adult

Hepatitis B | Hepatitis A

Belgium
GlaxoSmithKline

Completed

Persistence of Immunity Against Hepatitis B in 12-13 Year Old Adolescents After Infant Hepatitis B Vaccination

Hepatitis B

Germany
GlaxoSmithKline

Completed

Long Term Follow-up Study at Years 2, 3, 4 and 5 Where 2 Dosing Schedules of the Combined Hepatitis A and B Vaccine Were Compared

Hepatitis B | Hepatitis A

Australia, Belgium, Spain
GlaxoSmithKline

Completed

Study to Compare the Efficacy of GSK Biologicals' Adjuvants in Combination With the Antigen of the Hepatitis B Vaccine

Hepatitis B

Germany, Belgium
GlaxoSmithKline

Completed

Evaluation of Immune Memory to Twinrix or Comparator by Challenge Dose Administration 4 Years After Primary Vaccination

Hepatitis B | Hepatitis A

Belgium, Czechia
GlaxoSmithKline

Completed

Long-term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vaccine Injected According to a 0,1,6 Mth Schedule in Healthy Adults

Hepatitis B | Hepatitis A

Belgium
Merck Sharp & Dohme LLC

Completed

Modified Process Hepatitis B Vaccine in Japanese Young Adults (V232-062)

Hepatitis B
GlaxoSmithKline

Completed

Hepatitis B Antibody Persistence and Immune Response to Hepatitis B Vaccine Challenge in Previously Vaccinated Children

Hepatitis B

Germany
Merck Sharp & Dohme LLC

Completed

A Study of 2 Doses of a Hepatitis B Vaccine (V232 RECOMBIVAX HB) in Healthy Infants (V232-057)

Hepatitis B
Merck Sharp & Dohme LLC

Completed

Study of Recombinant Modified Process Hepatitis B Vaccine in Older Adults (V232-059)(COMPLETED)

Hepatitis B
GlaxoSmithKline

Completed

Immune Response to Hepatitis B Vaccine Challenge Dose in Subjects Who Received a Primary Neonatal Hepatitis B Vaccine.

Hepatitis B

Thailand
GlaxoSmithKline

Completed

LT F-up Study 16-20 Yrs After Vaccine Dose of Hepatitis B With/Without HBIg in Newborns to HBeAg+ Mothers

Hepatitis B

Thailand
GlaxoSmithKline

Completed

Persistence of Hepatitis B Antibody Levels & Immune Response to a Hepatitis B Vaccine Challenge

Hepatitis B

Germany
Massachusetts General Hospital

Completed

The Effect of Alendronate on the Immune Response to Hepatitis B Vaccine in Healthy Adults

Hepatitis B

United States
GlaxoSmithKline

Completed

Comparison of Monodose and Multidose Presentations of GSK Biologicals' Hepatitis B Vaccine in Terms of Immune Response

Hepatitis B

Belgium
University of Surrey

Completed

A Study to Characterise Immune Responses Following Immunisations With "Fendrix" or "Engerix B" Hepatitis B Vaccines

Hepatitis B

United Kingdom
GlaxoSmithKline

Withdrawn

Evaluation of the Long-term Hepatitis A and B Antibody Persistence in Healthy Adult Subjects, Primed 16 to 20 Years Earlier With GSK Biologicals' Combined Hepatitis A and B Vaccine, Twinrix® (SB208127) in Study HAB-084 (208127/084)

Hepatitis B | Hepatitis A

Czech Republic
GlaxoSmithKline

Completed

Acceptability of Hepatitis B Vaccination in General Population (PopCorn)

Hepatitis B
Beijing Municipal Science & Technology Commission

Unknown

Expression of Th9 Cells and Poor/Non-responsiveness to Hepatitis B Vaccination

Hepatitis B

China
National Taiwan University Hospital
National Science Council, Taiwan

Completed

The Hepatitis B Vaccine Booster Response Among the Youth Who Had Completed Neonatal Hepatitis B Vaccines

Hepatitis B

Taiwan
Henogen
GlaxoSmithKline

Completed

A Study to Compare the Immune Response and Safety Elicited by Henogen's Adjuvanted Hepatitis B Vaccine Compared to Aventis Pasteur MSD's Hepatitis B Vaccine in Pre-Dialysis and Dialysis Patients Who Responded to Previous Hepatitis B Vaccination But Lost Antibody.

Hepatitis B

Belgium, Czech Republic, Hungary
Henogen

Completed

Consistency Study of Three Lots of Henogen's Adjuvanted Hepatitis B Vaccine When Given in 0, 1 Month Schedule

Hepatitis B

Czech Republic
GlaxoSmithKline

Completed

Safety, Immunogenicity and Reactogenicity of Recombinant Hepatitis B Vaccine (Adjuvanted & New Formulation) and Engerix™-B

Hepatitis B

Austria
GlaxoSmithKline

Completed

Evaluation of Immunogenicity and Reactogenicity of Various Formulations of Recombinant Hepatitis B Vaccine

Hepatitis B

Austria
GlaxoSmithKline

Completed

Immunogenicity and Safety of GSK Biologicals' HBV-MPL Vaccine (2 Doses), and of Engerix™-B (3 Doses) in Healthy Adults

Hepatitis B

Belgium
GlaxoSmithKline

Completed

Safety and Immunogenicity of 3 Lots of GSK Biologicals' HBV-MPL Vaccine and Engerix™-B in Healthy Volunteers ≥ 15y

Hepatitis B

Australia, Czech Republic, Germany, Italy, Netherlands, Switzerland, United Kingdom
GlaxoSmithKline

Completed

Comparison of Immuno, Reacto and Safety of Recombinant Hepatitis B Vaccine With or Without MPL in Healthy Older Adults

Hepatitis B

Austria, Belgium, Denmark, Iceland
GlaxoSmithKline

Completed

Immunogenicity & Reactogenicity of HBV-MPL Vaccine and Engerix™-B in Healthy Adults Following 2 Different Schedules

Hepatitis B

Belgium
GlaxoSmithKline

Completed

Immunogenicity & Reactogenicity of Various Formulations of Recombinant Hepatitis B Vaccine With Different Adjuvants

Hepatitis B

Belgium
Centers for Disease Control and Prevention
Alaska Native Medical Center

Completed

VaxTeen Hepatitis B Vaccine Booster Study

Hepatitis

United States
St. Joseph's Health Care London

Completed

Efficacy Study of Combined Hepatitis A and Hepatitis B Vaccine to Protect Against Hepatitis B in Hemodialysis Patients

Hepatitis B

Canada

3

Subscribe